NCT00264472暂停1 期
A 2-Part Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU), and the Pharmacokinetics of 5-FU Given as: 5.0 mg ADH300004 With Escalating Doses of 5-FU Administered Orally 3 Weeks Out of 4 in Subjects With Refractory Solid Tumors (Part 1); or 5.0 mg ADH300004 With 5 FU Administered Orally as a Split Dose for 3 Weeks Out of 4 in Subjects With Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Gastric Cancer, Cervical Cancer, Prostate Cancer, or Breast Cancer (Part 2) (Adherex Protocol Number AHX-03-104)
Adherex Technologies, Inc.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Part 1: To determine the DLTs and MTD of the combination of ADH300004 and 5 FU administered orally in a weekly regimen, for 3 weeks with 1 week rest per cycle, in subjects with incurable solid tumors
研究概览
简要总结
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5 FU in subjects with refractory solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •> or = 18 years of age
- •Advanced or metastatic solid tumors:
- •Part 1: Histologically proven advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists
- •Part 2: Histologically proven advanced and/or metastatic solid tumor of one of the following 6 histologies, that is refractory to standard curative therapy or for which no curative therapy exists: HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer
- •Radiologically documented measurable or evaluable (non-measurable) disease
- •Adequate performance status and organ function, as evidenced by hematologic and biochemical blood testing
- •Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the last dose of ADH300004 in this study
排除标准
- •Cytotoxic chemotherapy, radiotherapy, or investigational drug within 28 days prior to study entry
- •Non-cytotoxic cancer therapy within 14 days prior to study entry
- •Portal hypertension with bleeding esophageal or gastric varices within the past 3 months
- •Ascites that is refractory to conservative management
- •Inability to take oral medication
- •Active peptic ulcer disease
- •Known hypersensitivity to 5-FU or ADH300004
- •Stroke, major surgery, or other major tissue injury within 30 days before study entry
结局指标
主要结局
Part 1: To determine the DLTs and MTD of the combination of ADH300004 and 5 FU administered orally in a weekly regimen, for 3 weeks with 1 week rest per cycle, in subjects with incurable solid tumors
时间窗: 4 weeks
Part 2: To determine the DLTs and MTD of the combination of ADH300004 and 5-FU administered orally as a split dose for 3 out of 4 weeks in subjects with HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic ResectionNeoplasmsNCT00264446Adherex Technologies, Inc.
终止
1 期
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular CarcinomaHepatocellular CarcinomaNCT00319683Adherex Technologies, Inc.
已完成
2 期
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02119026Prof. Dr. Werner Scheithauer120
已完成
不适用
Identification of the mechanisms of 5-fluorouracil (5-FU)-induced Gastrointestinal (GI) toxicity in human coloNL-OMON55582niversiteit Maastricht3
已完成
2 期
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral CancerBladder CancerNCT00003175Medical Research Council45